oxaliplatin pfizer 5 mg/ml infuusiokonsentraatti, liuosta varten
pfizer pfe finland oy - oxaliplatinum - infuusiokonsentraatti, liuosta varten - 5 mg/ml - oksaliplatiini
paracetamol/codein orion 500 mg / 30 mg tabletti
orion corporation - codeini phosphas hemihydricus,paracetamolum - tabletti - 500 mg / 30 mg - kodeiini ja parasetamoli
oxaplamyl 5 mg/ml infuusiokonsentraatti, liuosta varten
mylan ireland limited mylan ireland limited - oxaliplatinum - infuusiokonsentraatti, liuosta varten - 5 mg/ml - oksaliplatiini
ondansetron kalceks 2 mg/ml injektio-/infuusioneste, liuos
as kalceks - ondansetron hydrochloride dihydrate - injektio-/infuusioneste, liuos - 2 mg/ml - ondansetroni
pyrukynd
agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiset aineet - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.